ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1757

The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1712

The Lymph Node Microenvironment in SLE Mice Is Altered and Impairs Egress of T Lymphocytes

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1969

The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1685

The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2160

The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 2071

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1716

The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 2039

The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1827

The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2104

The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1802

The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2028

The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1795

Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1841

To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 2054

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].